@article{3d9ed03430ef4ca29496ef4e1d592e14,
title = "Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033",
abstract = "Purpose: It is currently unknown whether increasing radiation therapy (RT) volume has a negative impact on the health-related quality of life (HRQoL) of patients with low-grade glioma in the short term. The aim was to examine whether the size of the target volume is independently associated with HRQoL.Methods and Materials: We included patients who were treated with radiation therapy in the European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 study and who completed baseline HRQoL assessment. HRQoL was measured at baseline and every 3 months thereafter until progression, using the European Organisation for Research and Treatment of Cancer quality of life and brain cancer module questionnaires (QLQ-C30 and QLQ-BN20). We investigated whether there were associations between radiation volumes and (changes in) 4 preselected HRQoL scales (global health status, cognitive and social functioning, and fatigue). Also, we determined if radiation volumes were independently associated with a change in HRQoL over time.Results: We included 195 of 240 patients (81.3%) randomized to radiation therapy in this analysis. The brain volume receiving radiation therapy was not associated with (changes in) HRQoL during the first 24 months after radiation therapy. Over time, radiation volumes were also not independently associated with HRQoL. Notably, the occurrence of tumor progression was found to be associated with worse functioning and more fatigue.Conclusions: The brain target volume receiving focal radiation therapy in fractions of 1.8 Gy to a total of 50.4 Gy did not appear to be independently associated with HRQoL in high-risk patients with low-grade glioma in the short term, as opposed to tumor progression. However, the impact of radiation volumes on long-term HRQoL, as well as neurocognitive functioning, remains to be investigated. (C) 2019 Elsevier Inc. All rights reserved.",
keywords = "PHASE-III TRIAL, EUROPEAN-ORGANIZATION, PLUS PROCARBAZINE, RANDOMIZED-TRIAL, DOSE-RESPONSE, OPEN-LABEL, RADIOTHERAPY, BRAIN, TUMORS, ADULT",
author = "Linda Dirven and Reijneveld, {Jaap C.} and Taphoorn, {Martin J. B.} and Corneel Coens and El-Badawy, {Samy A.} and Tzahala Tzuk-Shina and Jose Bravo-Marques and Michael Back and Stalpers, {Lukas J. A.} and Roger Stupp and Baumert, {Brigitta G.} and Clemens Seidel",
note = "Funding Information: The EORTC 22033-26033 study was supported by Merck Sharpe & Dohme / Merck & Co, the Canadian Cancer Society, the Swiss Cancer League, the UK National Institutes of Health Research, the Australian National Health and Medical Research Council, the US National Cancer Institute, and the European Organisation for Research and Treatment of Cancer Research Fund.Conflict of interest: B.G.B. reports grants and personal fees from Merck (MSD) during the conduct of the study and personal fees from Noxxon, outside of the submitted work. J.C.R. reports nonfinancial support from Roche Nederland, outside of the submitted work. Funding Information: The EORTC 22033-26033 study was supported by Merck Sharpe & Dohme / Merck & Co, the Canadian Cancer Society, the Swiss Cancer League, the UK National Institutes of Health Research, the Australian National Health and Medical Research Council, the US National Cancer Institute, and the European Organisation for Research and Treatment of Cancer Research Fund.Conflict of interest: B.G.B. reports grants and personal fees from Merck (MSD) during the conduct of the study and personal fees from Noxxon, outside of the submitted work. J.C.R. reports nonfinancial support from Roche Nederland, outside of the submitted work. The EORTC 22033-26033 study was supported by Merck Sharpe & Dohme / Merck & Co, the Canadian Cancer Society, the Swiss Cancer League, the UK National Institutes of Health Research, the Australian National Health and Medical Research Council, the US National Cancer Institute, and the European Organisation for Research and Treatment of Cancer Research Fund. Conflict of interest: B.G.B. reports grants and personal fees from Merck (MSD) during the conduct of the study and personal fees from Noxxon, outside of the submitted work. J.C.R. reports nonfinancial support from Roche Nederland, outside of the submitted work. The authors would like to thank the patients for their participation in the European Organisation for Research and Treatment of Cancer 22033-26033 trial and all dedicated investigators, nurses, and other collaborators who were involved in the study. They would also like to thank Thierry Gorlia, statistician at the European Organisation for Research and Treatment of Cancer, for providing us with the data for this secondary analysis. The EORTC 22033-26033 study was supported by Merck Sharpe & Dohme / Merck & Co, the Canadian Cancer Society, the Swiss Cancer League, the UK National Institutes of Health Research, the Australian National Health and Medical Research Council, the US National Cancer Institute, and the European Organisation for Research and Treatment of Cancer Research Fund. Conflict of interest: B.G.B. reports grants and personal fees from Merck (MSD) during the conduct of the study and personal fees from Noxxon, outside of the submitted work. J.C.R. reports nonfinancial support from Roche Nederland, outside of the submitted work. Funding Information: The EORTC 22033-26033 study was supported by Merck Sharpe & Dohme / Merck & Co , the Canadian Cancer Society , the Swiss Cancer League , the UK National Institutes of Health Research , the Australian National Health and Medical Research Council , the US National Cancer Institute , and the European Organisation for Research and Treatment of Cancer Research Fund. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = may,
day = "1",
doi = "10.1016/j.ijrobp.2019.01.003",
language = "English",
volume = "104",
pages = "90--100",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Science",
number = "1",
}